David True
Rheumatology · Springfield, MONPI 1609854769
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Lundbeck LLC at 25.6% of the total. Reporting peaked in 2020 at $8,187 and has fallen 99.0% since, to $79 in 2025.
Across 511 payments — averaging $45.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$6K
- Eli Lilly$4K
- Sanofi$2K
- Boehringer Ingelheim International GmbH$1K
- Modernatx, Inc.$1K
- AbbVie$1K
- plus $7K from 25 others
Across 1,836 payments — averaging $8674.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7.5M
- Modernatx, Inc.$2.4M
- AbbVie$2M
- Boehringer Ingelheim$593K
- Biohaven Pharmaceutical Holding Company Ltd.$553K
- Biohaven Pharmaceuticals, Inc.$533K
- plus $2.3M from 15 others
What the payments were for
- Consulting fees$5,77425%
- Speaking & faculty fees$1,7107%
- Travel & lodging$5,09522%
- Food & beverage$10,47745%
- Education$3131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 23 | $5,990 |
| Eli Lilly | 46 | $4,131 |
| Sanofi | 8 | $1,838 |
| Boehringer Ingelheim International GmbH | 11 | $1,476 |
| Modernatx, Inc. | 12 | $1,405 |
| AbbVie(2 entities) | 61 | $1,273 |
| Amgen(2 entities) | 69 | $1,261 |
| Lilly USA, LLC | 58 | $1,044 |
| Johnson & Johnson | 41 | $726 |
| AstraZeneca | 15 | $680 |
| UCB, Inc. | 21 | $455 |
| Novartis | 24 | $402 |
| E.r. Squibb & Sons, L.L.C. | 11 | $388 |
| Biohaven Pharmaceuticals, Inc. | 22 | $347 |
| Mallinckrodt Hospital Products Inc. | 8 | $343 |
| Biohaven Pharmaceutical Holding Company Ltd. | 20 | $264 |
| GSK | 9 | $209 |
| Radius Health, Inc. | 10 | $186 |
| Bristol Myers Squibb | 9 | $185 |
| Janssen Scientific Affairs, LLC | 3 | $155 |
| Pfizer | 10 | $124 |
| Gilead | 2 | $121 |
| Teva Pharmaceuticals USA, Inc. | 3 | $95 |
| Genentech USA, Inc. | 5 | $82 |
| Fresenius Kabi USA, LLC | 3 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $48 |
| Biogen | 1 | $23 |
| Mylan Institutional Inc. | 1 | $18 |
| Octapharma USA, Inc. | 1 | $16 |
| Pacira Therapeutics, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,369 in reported general payments places this provider in the 85th percentile of 134 rheumatology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel MiniEtanercept | 11 | $94,815 |
| Actemra ActpenTocilizumab | 13 | $64,900 |
| Hydroxychloroquine Sulfate | 35 | $1,405 |
| Leflunomide | 23 | $838 |
| MethotrexateMethotrexate Sodium | 33 | $696 |
| Prednisone | 33 | $176 |
| Trazodone Hcl | 15 | $85 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Springfield
- Joseph MayusSpringfield$4K
- Alexis HowardSpringfield$4K
- Bradley BohmanSpringfield$3K
- Anne WinklerCarthage$1.6M
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Mark BoxKansas City$304K
- Sona KamatSaint Louis$268K
- Robert JacksonMemphis$152K
- Richard BrasingtonSaint Louis$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.